We found that LT recipients with HCC exceeding the Milan Criteria could benefit from sirolimus‐based immunosuppression,36, 37 and the low TSC1/2 expression subgroup (higher tumor activity) benefited the most.38, 39. The gene discussed is TSC1; the disease is hepatocellular carcinoma.